Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In this episode, Brad S. Kahl, MD, and Anthony Mato, MD, MSCE, discuss their choices of 3 recent important trials presented at ASCO 2022 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The discussion will include analyses of:
Professor of Medicine
Department of Medical Oncology
Washington University School of Medicine
St Louis, Missouri
Associate Professor
Division of Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York
This program has been made available online.
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
Expert faculty answer audience questions from a live satellite symposium presented at ASCO 2022 on the management of MDS, from Clinical Care Options (CCO)
Commentary on the evolving therapeutic landscape in peripheral T-cell lymphomas with a focus on EZH1/2 inhibition, from Clinical Care Options (CCO)
Video featuring Jesús Berdeja, MD, and Sagar Lonial, MD, discussing the latest evidence on approved and investigational CAR T-cell therapies for multiple myeloma, from Clinical Care Options (CCO)
Expert webcast recording of live webinar on selecting therapy and managing toxicities for indolent B-cell lymphomas, from Clinical Care Options (CCO)
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.